Literature DB >> 7569613

[Snake bites in children: antivenom early reaction frequency in patients pretreated with histamine antagonists H1 and H2 and hydrocortisone].

F Bucaretchi1, J L Douglas, M R Fonseca, F A Zambrone, R J Vieira.   

Abstract

Type and frequency of early reactions (ER) were studied in 24 children aging 2-14 years victims of snake bites who received pretreatment with histamine antagonists H1 (dextrochlorfeniramine) and H2 (cimetidine or ranitidine) and hydrocortisone from 1989 to 1993. None of them had atopy nor received any type of anti-venoms(AV) and antitoxins before. Of 24 children, 15 received bothropic AV (ER in 5), 7 crotalic AV (ER in 5), 1 crotalic plus crotalic-bothropic AV, and 1 elapidic AV (ER in 1). In 3 children severe early reactions were observed and they were classified as severe crotalic accident. Results suggest that pre-treatment did not offer safety protection at the appearance of early reactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7569613     DOI: 10.1590/s0036-46651994000500010

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  4 in total

Review 1.  Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis.

Authors:  Abdulrazaq G Habib
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

2.  Safety and efficacy of a freeze-dried trivalent antivenom for snakebites in the Brazilian Amazon: An open randomized controlled phase IIb clinical trial.

Authors:  Iran Mendonça-da-Silva; Antônio Magela Tavares; Jacqueline Sachett; José Felipe Sardinha; Lilian Zaparolli; Maria Fátima Gomes Santos; Marcus Lacerda; Wuelton Marcelo Monteiro
Journal:  PLoS Negl Trop Dis       Date:  2017-11-27

Review 3.  Antivenom therapy: efficacy of premedication for the prevention of adverse reactions.

Authors:  Victor Morais
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-02-28

Review 4.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.